ArriVent BioPharma, Inc.
About ArriVent BioPharma, Inc.
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$166.3M
- Total assets
- $333.2M
- Market cap
- $1.4B
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $177.5M
- Operating income
- -$177.5M
- Net income
- -$166.3M
- EPS (basic)
- $-4.32
- EPS (diluted)
- $-4.32
Balance sheet
- Total assets
- $333.2M
- Current assets
- $332.9M
- Total liabilities
- $25.9M
- Current liabilities
- $25.9M
- Shareholders’ equity
- $307.2M
Cash flow
- Operating cash flow
- -$160.6M
- Investing cash flow
- -$71.2M
- Financing cash flow
- $203.1M
- Net cash flow
- -$28.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.4B
- EPS (diluted)
- $-4.32
- Shares outstanding
- 46.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 26, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $166.3M.
- Trading 8% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ArriVent BioPharma, Inc..
Write a review
News about ArriVent BioPharma, Inc.
News & sentiment via Polygon.io
